Benzinga | Jan 25, 2021 08:33AM EST

DURECT Corporation Announces First Patient Dosed In Phase 2b AHFIRM Study Of DUR-928 In Severe Alcohol-Associated Hepatitis

CUPERTINO, Calif., Jan. 25, 2021 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.